Absci shares jump as analyst lauds 'practical' AI drug company
"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...
Cathie Wood's ARK sells Accolade stock, buys more Absci
Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort ...
Absci initiated with a Buy at Needham
Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...
bovnews4d
What’s Fueling Absci Corp (ABSI) Stock’s -26.93% Loss Below Its 200-Day SMA?
Absci Corp (ABSI) stock saw a modest uptick, ending the day at $2.9 which represents a slight increase of $0.10 or 3.57% from the prior close of $2.8. The stock opened at $2.86 and touched a low of $2 ...
Top 10 Medical AI Stocks on Wall Street’s Radar
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
AbSci (ABSI) Gets a Buy from Truist Financial
Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...
manilatimes17d
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...